Picard Medical, INC 8-K filings

Picard Medical will present in vitro data on its fully implantable Emperor Total Artificial Heart at the ISMCS 2025 conference in Vienna.

Picard Medical's subsidiary, SynCardia, successfully completed the first in vivo implantations of its next-generation Emperor Total Artificial Heart, marking a significant advancement.

Picard Medical, Inc. announced strong third-quarter 2025 financial results, highlighted by a successful IPO, significant revenue growth, and strategic board and patent expansions.

Picard Medical, Inc. issued a statement addressing recent stock price volatility, asserting no undisclosed material changes in its operations or financial condition.

Picard Medical, Inc. stockholders approved an amendment to its 2021 Equity Incentive Plan, increasing available shares to 18 million and adding warrants as an award type.

Picard Medical, Inc. announced the full exercise of its IPO over-allotment option, generating an additional $2.55 million in gross proceeds.

Picard Medical, Inc. successfully priced and closed its Initial Public Offering of 4,250,000 shares at $4.00 per share, raising $17 million in gross proceeds, and commenced trading on the NYSE American.